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These data were presented in part at the 21st International AIDS Conference (AIDS 2016) 18 to 22 July 2016 in Durban, South Africa.

1. Introduction {#jia225326-sec-0005}
===============

South Africa has the largest HIV treatment programme in the world, with more than 3.1 million people on antiretroviral therapy (ART) [1](#jia225326-bib-0001){ref-type="ref"}. Because of a gradual, planned funding reduction from the U.S. President\'s Emergency Plan for AIDS Relief (PEPFAR) to promote transition to full country‐led fiscal responsibility, the South African government has continued to expand its national programme [2](#jia225326-bib-0002){ref-type="ref"}, [3](#jia225326-bib-0003){ref-type="ref"}, [4](#jia225326-bib-0004){ref-type="ref"}, [5](#jia225326-bib-0005){ref-type="ref"}, [6](#jia225326-bib-0006){ref-type="ref"}. As part of this expansion, patient care has shifted from hospital‐based, doctor‐managed clinics towards nurse‐led, public sector community clinics, resulting in large‐scale patient transfers [7](#jia225326-bib-0007){ref-type="ref"}, [8](#jia225326-bib-0008){ref-type="ref"}.

The clinical implications of patient transfers are difficult to assess, but have become increasingly important as the South African government focuses on strategies to improve linkage to and retention in HIV care [9](#jia225326-bib-0009){ref-type="ref"}, [10](#jia225326-bib-0010){ref-type="ref"}. Limited available data show similar clinical outcomes for those transferred to primary health clinics compared with hospital‐based clinics [11](#jia225326-bib-0011){ref-type="ref"}, [12](#jia225326-bib-0012){ref-type="ref"}, [13](#jia225326-bib-0013){ref-type="ref"}. However, these studies reflect outcomes of selected, clinically stable patients referred to community programmes [14](#jia225326-bib-0014){ref-type="ref"}, [15](#jia225326-bib-0015){ref-type="ref"}, [16](#jia225326-bib-0016){ref-type="ref"}. In extant studies, receiving clinic nurses were provided with additional training in the context of a clinical trial, the sickest patients were still cared for by physicians, and a substantial fraction of patients refused the referral [12](#jia225326-bib-0012){ref-type="ref"}, [14](#jia225326-bib-0014){ref-type="ref"}. Strategies for evaluating linkage to and retention in community clinic care under "real world" programmatic conditions will prove invaluable for designing programmes that maximize continuity of clinical HIV care following transfers.

Data from the National Health Laboratory Service (NHLS), South Africa\'s repository for all public sector laboratory measurements, have previously been used to evaluate the effectiveness of certain government‐funded HIV‐programmes [17](#jia225326-bib-0017){ref-type="ref"}, [18](#jia225326-bib-0018){ref-type="ref"}, [19](#jia225326-bib-0019){ref-type="ref"}, to identify patterns of the country\'s TB epidemic [20](#jia225326-bib-0020){ref-type="ref"}, [21](#jia225326-bib-0021){ref-type="ref"}, and to determine cancer incidence rates among HIV‐infected patients [22](#jia225326-bib-0022){ref-type="ref"}. While we have previously assessed the completeness and accuracy of the NHLS Corporate Data Warehouse (CDW) and have validated the NHLS CDW as a reliable data source [23](#jia225326-bib-0023){ref-type="ref"}, the use of NHLS data to evaluate the outcome of patient transfers has been limited [24](#jia225326-bib-0024){ref-type="ref"}. Despite that, it has been shown to be an effective tool for more accurately estimating lost to follow‐up for women transferring to postpartum care [25](#jia225326-bib-0025){ref-type="ref"}, [26](#jia225326-bib-0026){ref-type="ref"}. With its large size and comprehensive coverage (\>80%) of the population [17](#jia225326-bib-0017){ref-type="ref"}, [27](#jia225326-bib-0027){ref-type="ref"}, the NHLS CDW could serve as an important tool for tracking patients following healthcare facility closures or other care transfers. As programmes across South Africa continue to transfer patients from non‐governmental organizations to government‐funded, community clinics, identifying methods to inform the success of these transfers is critical.

Following a large‐scale transfer from a physician‐run, hospital‐based, PEPFAR‐funded HIV programme in Durban to nurse‐led, community‐based clinics, we sought to demonstrate the utility of NHLS data to evaluate success of transfer and to determine predictors of slower re‐linkage to care.

2. Methods {#jia225326-sec-0006}
==========

2.1. Study site {#jia225326-sec-0007}
---------------

McCord Hospital was a semi‐private, general hospital in KwaZulu‐Natal serving a predominantly urban population from the greater Durban area. The Sinikithemba HIV clinic at McCord, which became a PEPFAR‐funded site in 2004, was an integral part of the South African ART scale‐up and initiated over 10,000 patients on ART [28](#jia225326-bib-0028){ref-type="ref"}. Sinikithemba served a predominantly African, Zulu‐speaking population. Patients were seen by both nurses and doctors who were available for daily consultations and took on medically complex cases. The clinic was considered a local Center of Excellence and had a monitoring and evaluation team and an electronic medical record. Due to loss of PEPFAR funding, the clinic closed in June 2012.

All patients who returned to the clinic for clinical appointments, laboratories or pharmacy refills to Sinikithemba between 12 March 2012 and 30 June 2012, the "transfer period," were referred for transfer to one of 171 different clinics in the Durban area. Patients taking first‐line ART were transferred to primary healthcare clinics (PHC); those taking second‐line line ART were transferred to community health clinics (CHC), which provide a higher level of services than PHCs. Patients with comorbidities requiring medications not on the South African Essential Drug List were referred to hospital‐based clinics. Data collected by the clinic at the time of transfer included sex, age, most recent CD4 count and viral load (VL) prior to transfer, and the type of clinic to which the participant were referred. We have previously reported on the Sinikithemba transfer process evaluating linkage to the initial transfer clinic visit and patient attitudes about their transfer experience using telephone surveys combined with validated clinic visits [28](#jia225326-bib-0028){ref-type="ref"}, [29](#jia225326-bib-0029){ref-type="ref"}. The current study seeks to assess linkage to HIV care post‐transfer using availability of CD4 or VL testing within approximately three years of transfer as a proxy for successful transfer.

2.2. Study population {#jia225326-sec-0008}
---------------------

The study population included adults on ART who visited the Sinikithemba HIV clinic during the transfer period. Patients \<18 years old on 30 June 2012 were excluded, as we focused on the adult transfer process. For the post‐transfer linkage assessment, we excluded patients who were referred to a private doctor, because we did not expect these individuals to have laboratory data in the NHLS system. Participants provided verbal consent for study participation at the time of transfer. The study protocol was approved by the McCord Hospital Research Ethics Committee (Durban, South Africa) and the Partners Human Research Committee (2012‐P‐001,122/1, Boston, MA).

2.3. National Health Laboratory Service {#jia225326-sec-0009}
---------------------------------------

The National Health Laboratory Service was established in 2001 and supports national and provincial health departments in South Africa. It is the largest diagnostic pathology service in the country, providing laboratory and related public health services to over 80% of the population through a national network of 265 laboratories [17](#jia225326-bib-0017){ref-type="ref"}. The NHLS performs all public sector CD4 count and VL monitoring and maintains a Corporate Data Warehouse (CDW) that serves as a national repository for laboratory data from the public sector. Healthcare workers at each public health facility complete laboratory requisition forms which accompany each sample submitted to the CDW. All data, including patient identifiers, name of facility, date of sample and tests requested, are sent to the CDW and are captured electronically by the NHLS information system in real time. We have previously evaluated the completeness and accuracy of the NHLS CDW using a novel data crossmatching method [23](#jia225326-bib-0023){ref-type="ref"}.

2.4. Data collection and processing {#jia225326-sec-0010}
-----------------------------------

We sought to estimate the cumulative frequency of linkage using evidence of post‐transfer CD4 count and VL after 30 June 2012. We sent a list of all 4257 McCord Hospital transfer patients with corresponding identifiers (patient ID, first name, surname, sex, date of birth, South African ID) to the NHLS to obtain laboratory records within approximately three years of the transfer (the last NHLS records extracted were in June 2015). To assist with the matching process, we also sent the last known CD4 count and VL values and dates recorded in the electronic medical record at McCord Hospital. From the original 4257 patient list, duplicated patient IDs (n = 12), patients \<18 years old on 30 June 2012 (n = 337), and patients referred to private clinics (n = 15) were removed from the data sets prior to matching, resulting in a cohort of 3893 transfer patients for potential matching with NHLS laboratory data. Although laboratory monitoring recommendations have changed over time, laboratory monitoring of some kind (CD4 or VL or both) have been recommended every six or twelve months in South Africa for the duration of the study period.

We assessed deaths by cross‐matching patients with the South African National Population Register using South African Identification Numbers in May 2014. Valid South African Identification Numbers were available for 94% of patients. More than 90% of deaths nationwide are captured in this register [30](#jia225326-bib-0030){ref-type="ref"}.

2.5. Assessment of cumulative frequency of linkage after transfer {#jia225326-sec-0011}
-----------------------------------------------------------------

As we reported previously, after extensive efforts assessing the quality of subject matching for data provided by the NHLS, we determined that 99.7% of the individuals were correctly matched [23](#jia225326-bib-0023){ref-type="ref"}. Based on this result, we previously recommended that matches from NHLS be accepted without extensive review, and have followed this approach in the current analysis [23](#jia225326-bib-0023){ref-type="ref"}. Patients who had at least one NHLS record, whether CD4 count or VL, within approximately three years after the end of the transfer period were considered re‐linked. We also assessed re‐linkage rates at six months, one year and two years after the end of the transfer period.

2.6. Statistical analysis {#jia225326-sec-0012}
-------------------------

Standard life table methods were used in the analysis. Proportions linked at various time periods after the end of the transfer period were estimated using Kaplan‐Meier methods. We used a Cox proportional hazards model to examine the hazard ratio of slower time to re‐linkage (having no post‐transfer measurements in the CDW over time). Predictors considered included sex, age, CD4 count at transfer (three levels: \<200/μL; 200 to 500/μL; and \>500/μL), virological suppression pre‐transfer (three categories: suppressed, defined as NHLS coding of \<400 copies/mL; not suppressed; and no VL data available), duration on ART prior to transfer (three categories: \<3 months; three months to one year; and \>1 year) and type of transfer facility. We excluded a total of 44 individuals with missing values for CD4 (3 individuals), ART duration (23 individuals), or missing location of future care (21 missing); several individuals were missing data on more than variable. We retained missing VL as a separate category, due to the large number of missing records (298). We calculated hazard ratios (HR) with 95% confidence intervals (CI) for each individual factor. We then developed a multivariable model including all factors other than VL that were statistically significant in the univariate analysis and calculated adjusted hazard ratios (aHR). The goal of the model was to identify factors associated with higher risk of failure to re‐link to care after clinic transfer to help guide programmes when considering which patients may be higher risk for LTFU post transfer. Statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC).

3. Results {#jia225326-sec-0013}
==========

3.1. Cohort characteristics {#jia225326-sec-0014}
---------------------------

Of the 3893 participants included in the analysis, 41% of the cohort was male and median age was 39 (interquartile range (IQR) 34 to 46) (Table [1](#jia225326-tbl-0001){ref-type="table"}). The majority of patients had CD4 counts above 200/μL at transfer (\<200/μL 16%, 200 to 500/μL 56%, \>500/μL 29%) and 98% of patients with available VL data were virologically suppressed. As 298 patients (8%) did not have a VL available, however, the proportion known to be suppressed is only 90%. Among all participants, over 80% had been on ART for more than a year upon transfer (\<3 months 5%, three months to one year 13%, \>1 year 82%). Most patients were transferred to public sector clinics (PHC 67%, CHC 21%, hospital 12%). Fifteen patients (0.4%) were assigned to private doctors and were excluded as we did not expect that they would have laboratory tests through the NHLS. Eighty‐four patients (2.2%) are known to have died after transfer but are included in our population for assessing re‐linkage to care after transfer based on the availability of NHLS laboratory testing after the transfer period.

###### 

Characteristics of patients transferred from McCord Hospital to community‐based clinics in Durban, South Africa

  Patient characteristic                                                                      Total N = 3893
  ------------------------------------------------------------------------------------------- ----------------
  Sex (male), N (%)                                                                           1586 (41)
  Age, median (IQR)                                                                           39 (34 to 46)
  Age\<30, N (%)                                                                              406 (10)
  CD4 count at transfer, N (%)[a](#jia225326-note-0003){ref-type="fn"}                        
  \<200/μL                                                                                    606 (16)
  200 to 500/μL                                                                               2164 (56)
  \>500/μL                                                                                    1120 (29)
  Viral load, % known suppressed at transfer, N (%)[b](#jia225326-note-0003){ref-type="fn"}   3514 (90)
  Duration of ART treatment, N (%)[c](#jia225326-note-0003){ref-type="fn"}                    
  \<3 months                                                                                  186 (5)
  3 months to 1 year                                                                          523 (13)
  \>1 year                                                                                    3161 (82)
  Location of future care, N (%)[d](#jia225326-note-0003){ref-type="fn"}                      
  Primary healthcare clinic                                                                   2609 (67)
  Community health clinic                                                                     811 (21)
  Hospital‐based clinic                                                                       452 (12)
  Number of known deaths in the cohort, N (%)                                                 84 (2)

ART, antiretroviral therapy.

^a^Based on the last CD4 count value taken at McCord excluding three missing values; ^b^based on the last viral load value taken at McCord, with 298 missing values treated as not suppressed; ^c^based on the total time in years between the ART initiation date and the transfer date excluding 23 missing values; ^d^Excluding 21 "unknown" locations of future care.
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3.2. Cumulative frequency of linkage to care over time {#jia225326-sec-0015}
------------------------------------------------------

Among the 3893 patients transferred, 61% (2377) of these patients were re‐linked to care by the end of our study period (Figure [1](#jia225326-fig-0001){ref-type="fig"}). Twenty‐three percent were linked within six months of the end of the transfer period, 44% were linked within one year of the transfer period and 57% were linked within two years of the end of the transfer period. Among the 84 patients known to have died, 33 (39%) had NHLS laboratory data after transfer and before death.

![The proportion of individuals in care prior to transfer or linked to care after transfer\
The left axis shows the proportion of the total population in care from the start of the study, while the right axis shows the proportion of those who have re‐linked among the total population by the end of the study period. We assumed all 3893 individuals were in‐care on 1 March 2012, shortly before the transfers began. The number in care then decreased as they completed their final visit at the initial site. The proportion having a CD4 count or viral load measurement in the National Health Laboratory System (NHLS) Corporate Data Warehouse (CDW) over time after the end of the transfer period is the solid line. Time in months is shown along the horizontal axis, with time=0 the end of the transfer period. Confidence bands (shaded lines) depict the 95% Hall‐Weller confidence interval, which provides an approximate 95% coverage throughout the entire re‐linkage period. No confidence interval is shown for the data prior to transfer or for the early period (approximately first month) after transfer. Twenty‐three percent of the original population were linked within six months of the end of the transfer period, 44% were linked within one year, 57% were linked within two years, and 61% were linked within approximately three years.](JIA2-22-e25326-g001){#jia225326-fig-0001}

3.3. Predictors of slower re‐linkage to care {#jia225326-sec-0016}
--------------------------------------------

In the unadjusted analyses, male sex (hazard ratio 1.19 (1.09 to 1.30)), age \<30 (compared to age ≥30 years, hazard ratio 1.27 (1.10 to 1.47)), CD4 count \<200/μL (compared to \>500/μL, hazard ratio 1.38 (1.20 to 1.58), and shorter duration of ART (\<3 months hazard ratio 3.96 (2.90 to 5.40) and three months to one year hazard ratio 1.35 (1.19 to 1.54), both compared to \>1 year) were associated with slower re‐linkage over time (Table [2](#jia225326-tbl-0002){ref-type="table"}). Missing VL data were a significant predictor of slower linkage (hazard ratio 3.31 (2.63 to 4.17)) but lack of suppression was not an important predictor (hazard ratio 1.12 (0.83 to 1.51)). The type of clinic to which participants were referred at transfer was also not associated with failure to re‐link.

###### 

Predictors of not having post‐transfer measurement data in the NHLS CDW

  Patient characteristic           Linked N = 2353 (61%)   Not linked N = 1496 (39%)   Hazard ratio (95% CI)   Adjusted hazard ratio model (95% CI)[a](#jia225326-note-0005){ref-type="fn"}
  -------------------------------- ----------------------- --------------------------- ----------------------- ------------------------------------------------------------------------------
  Sex (male), N (%)                901 (38)                672 (45)                    1.19 (1.09 to 1.30)     1.20 (1.10 to 1.31)
  Age \<30, N (%)                  210 (9)                 187 (13)                    1.27 (1.10 to 1.47)     1.12 (0.96 to 1.30)
  CD4 count at transfer, N (%)                                                                                 
  \<200/μL                         310 (13)                294 (20)                    1.38 (1.20 to 1.58)     1.04 (0.90 to 1.20)
  200 to 500/μL                    1329 (57)               807 (54)                    1.07 (0.97 to 1.18)     0.98 (0.89 to 1.08)
  \>500/μL                         714 (30)                395 (26)                    ref                     ref
  Viral load, N (%)                                                                                            
  Suppressed at transfer           2233 (95)               1244 (83)                   ref                     --
  Not suppressed at transfer       45 (2)                  33 (2)                      1.12 (0.83 to 1.51)     --
  Missing                          75 (3)                  219 (15)                    3.31 (2.63 to 4.17)     --
  ART duration, N (%)                                                                                          
  \<3 months                       41 (2)                  144 (10)                    3.96 (2.90 to 5.40)     3.80 (2.77 to5.21)
  3 months to 1 year               270 (11)                246 (16)                    1.35 (1.19 to 1.54)     1.32 (1.15 to 1.51)
  \>1 year                         2042 (87)               1106 (74)                   ref                     ref
  Location of future care, N (%)                                                                               
  Primary healthcare clinic        1567 (67)               1029 (69)                   ref                     --
  Community health clinic          510 (22)                295 (20)                    0.94 (0.85 to 1.04)     --
  Hospital‐based clinic            276 (12)                172 (11)                    0.92 (0.81 to 1.06)     --

A total of 44 individuals (24 linked; 20 not linked) were excluded for missing one or more of CD4, ART duration, or location of future care. ART, antiretroviral therapy; CDW, Corporate Data Warehouse; NHLS, National Health Laboratory Service; ref, reference group.

Model adjusted for sex, age, CD4 count at transfer, and time on ART prior to transfer.

John Wiley & Sons, Ltd

### 3.3.1. Multivariable model {#jia225326-sec-0017}

Because only lack of VL data, strongly associated with shorter duration on ART (data not shown) was a significant predictor of slower linkage, VL was not included in the multivariable model. Males were more likely to be unlinked (adjusted hazard ratio 1.20 (1.10 to 1.31)) but age and CD4 count were no longer significant predictors (both *p* \> 0.10) (Table [2](#jia225326-tbl-0002){ref-type="table"}). Being on ART for a shorter duration at transfer (\<3 months, adjusted hazard ratio 3.80 (2.77 to 5.21); three months to one year, adjusted hazard ratio 1.32 (1.15 to 1.51), each compared to \>1 year) also increased the hazard of not being linked.

4. Discussion {#jia225326-sec-0018}
=============

We assessed CD4 count or VL testing as a proxy for successful transfer of HIV care following a large‐scale transfer from McCord Hospital in Durban to nurse‐led, community‐based clinics by obtaining patient data from the NHLS CDW. We found that 2377 of the 3893 patients eligible for post‐transfer assessment (61%) had evidence of a post‐transfer, follow‐up visit based on NHLS CD4 count and VL data at approximately three years. We consider 61% to be a low estimate, based on the 221 who reported transferring to a private doctor in our prior study [28](#jia225326-bib-0028){ref-type="ref"}. These findings are consistent with systematic reviews estimating 70% retention in care at 24 months among patients on ART in sub‐Saharan Africa [31](#jia225326-bib-0031){ref-type="ref"}, [32](#jia225326-bib-0032){ref-type="ref"}. A more recent review focusing on retention in care between 2008 and 2013 in South Africa estimated an 18‐month retention rate of 71% [33](#jia225326-bib-0033){ref-type="ref"}. While these rates are comparable with our estimate, these studies do not exclusively focus on cohorts of transferred or "down‐referred" patients who may face greater risks of disruption of care and loss to follow‐up. However, our estimate is also consistent with a study evaluating national retention in South Africa\'s HIV programme accounting for patient transfers estimating a 63% retention rate after six years [24](#jia225326-bib-0024){ref-type="ref"} and with a study using NHLS data to assess postpartum transfers to general ART clinics, which found 65% of women linked and in care at 24 months [26](#jia225326-bib-0026){ref-type="ref"}.

In the multivariable analysis, male sex was a significant predictor of not having a post‐transfer record found in the NHLS CDW. Other factors that we evaluated (age, CD4 count at transfer and type of transfer facility) were not significantly associated with not having a post‐transfer record. These findings are consistent with our results from a previous study evaluating linkage to an initial transfer clinic visit, in which we found that age and most recent CD4 count were not associated with failure to be found at an assigned validation clinic [28](#jia225326-bib-0028){ref-type="ref"}. We previously estimated that 26% of patients continued care at clinics different than the assigned transfer clinic [28](#jia225326-bib-0028){ref-type="ref"}. Previous studies have shown that males typically have worse outcomes than females at every step of the HIV care cascade [34](#jia225326-bib-0034){ref-type="ref"}, [35](#jia225326-bib-0035){ref-type="ref"}. Male sex has emerged as a predictor of poor retention in care in a number of settings in sub‐Saharan Africa [32](#jia225326-bib-0032){ref-type="ref"}; our finding that male sex is associated with higher risk of not having a post‐transfer record in the NHLS CDW is consistent with these data.

In the ART duration adjusted model, spending \<3 months on ART prior to transfer substantially increased the risk of not having a post‐transfer record. As detectable viral load was not a predictor of slower linkage, and missing VL information was strongly associated with transfer within three months of starting ART, ART duration, rather than viral suppression, may be a more appropriate measure for defining "high risk" transfer patients.

There are several limitations to using national laboratory data as a marker of cumulative frequency of linkage to care. Our results are an estimate of patients who re‐linked to care following transfer from McCord Hospital. This estimate is lower and may be more accurate than our previous estimate of 82%, which was based on patient self‐report of re‐linkage and validation of an initial clinic visit for a subset of patients [28](#jia225326-bib-0028){ref-type="ref"}. We have previously assessed the completeness and accuracy of the NHLS CDW by matching patient identifiers and pretransfer CD4 and VL test results from the McCord Hospital dataset to data returned by NHLS; we reported that NHLS did not find a match for 10% of the patients in the transfer cohort [23](#jia225326-bib-0023){ref-type="ref"}, which may have also affected the ability to match post‐transfer laboratories for a small proportion of patients. It is also possible that patients in care post‐transfer were classified as "not re‐linked" because they were not receiving guideline concordant CD4 count and VL monitoring at their new clinical site. Additionally, many more patients reported attending private sector clinics than were assigned to them at the time of transfer. If these private clinics used private laboratories, then these patients would not be expected to have CD4 count and VL data in the NHLS system even if they had linked to care. Removing these individuals from our potential pool would lead to a higher linkage rate. By focusing on laboratory data, we were unable to examine the reasons for gaps in linkage or to assess the quality of care received. The truncated ascertainment of outcomes and the fact that participants were on ART at transfer may explain the relatively low rate of mortality in the setting of a low rate of re‐linkage.

Despite the drawbacks of this methodology, this study has several important strengths. Using NHLS data can transcend the limitations of collecting and analysing data within individual programmes, which presents challenges such as differences in record‐keeping methods and marked variability in how patients are identified. The ability to accurately classify "lost to follow‐up" patients as having actually transferred care elsewhere is important for evaluating the quality of the national governmental ART programme, especially as known Centers of Excellence have been disbanded [36](#jia225326-bib-0036){ref-type="ref"}, [37](#jia225326-bib-0037){ref-type="ref"}. The NHLS CDW is centralized, comprehensive and offers wide coverage of public clinics across the country; it therefore represents a useful tool for helping track patients who change their service provider.

5. Conclusions {#jia225326-sec-0019}
==============

The cumulative frequency of linkage to care after large‐scale patient transfers is difficult to assess but has become increasingly important as PEPFAR funding in South Africa decreases and patient care transitions to public sector community clinics. We found that a national data set collected for clinical purposes may be used for evaluating linkage of individual patients within public, government‐funded clinics. This ability to track patients may not only aid in the evaluation of re‐linkage and retention outcomes following HIV‐clinic closures and patient transfers but may also serve as an effective method to study patient flow and movement more generally within the HIV care system in South Africa, such as following transfer to postpartum HIV care. Additionally, this study utilizes NHLS data in a novel way. While NHLS CDW data have been used in several cross‐sectional studies [17](#jia225326-bib-0017){ref-type="ref"}, [18](#jia225326-bib-0018){ref-type="ref"}, [19](#jia225326-bib-0019){ref-type="ref"}, [20](#jia225326-bib-0020){ref-type="ref"}, [21](#jia225326-bib-0021){ref-type="ref"}, they have only been used in one longitudinal cohort study involving South Africa\'s National Cancer Registry [22](#jia225326-bib-0022){ref-type="ref"}. This methodology may be useful in the assessment of similar large‐scale transfers in other sub‐Saharan African countries with PEPFAR‐funded clinics and national electronic laboratory databases [38](#jia225326-bib-0038){ref-type="ref"}. For those who fail to link after transfer, these data could also direct efforts to reinforce linkage and avoid the morbidity and mortality associated with interruptions in care.
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